Cellworks TRI Products for Physicians
Cellworks provides oncologists two products to assist in treating patients diagnosed with specific oncology indications. Cellworks simulates the effectiveness of FDA-approved drugs using the molecular and genomic profile of the patient’s tumor.
SINGULATM Standard Care Response:
Cellworks SingulaTM provides physicians with transparent predictions of a treatment-naive patient’s response to standard care therapies for a given indication, their Therapy Response Index (TRI), by biosimulating the impact of each drug using NGS data from a biopsy or altered blood cells.
By predictively separating responders from non-responders, the physician has actionable decision making ability for optimized therapy. This can save vital time for the patient as well as control treatment costs. Say you, the physician, are presented with an MDS patient who has TET1, TET2, MTHFR, MTRR, TP53, APC, AXIN2 and ASXL1 mutations and a complex cytogenetic profile with loss of various chromosomal segments. SingulaTM can help guide you whether the patient with this set of genomic aberrations is likely to respond to an MDS standard care drug like Azacitidine or Lenalidomide.
SingulaTM is best suited for treatment-naïve patients.
VENTURATM Ideal Combination:
Cellworks VenturaTM informs physicians of relapsed or refractory patients’ response to combinations of FDA approved drugs, within and outside Standard Care, their Therapy Response Index (TRI), by biosimulating their impact on the patient’s genomic aberrations.
After the standard care therapies are exhausted, or after the patient has relapsed, the current protocol is to send the patient to clinical trials or to palliative care. Cellworks offers another option. VenturaTM informs you, the physician, of the likely ideal combination of all FDA-approved drugs to produce the response in the patient. In determining this optimal combination, on-label oncology drugs, off-label oncology drugs and non-oncology drugs are all investigated before a recommendation is made.
Say you, the physician, are presented with an AML patient who has HER2, FGFR4, IL4R, IL6R, IL7, TET1, DNMT3L mutations, and various other genes have copy number variations and are amplified (ACLY, NRG1, FGFR1, FGFR3, LYN) or deleted (TET3). VenturaTM will help guide you as to which combination of FDA-approved drugs this AML patient is likely to respond to.
VenturaTM is best suited for refractory or relapsed patients.
Personalized Cancer Therapy
The Cellworks process begins once an NGS report has been produced. A key barrier to adoption of NGS reports has been the lack of clinical utility. While evaluating a patient’s disease status with difficult options for treatment decisions, the NGS report now adds an additional level of complexity without necessarily providing anymore clarity or guidance towards the ultimate decision regarding treatment. Cellworks increases clinical utility and adoption of NGS by understanding the clinician’s needs. Cellworks Therapy Response Index (TRI) reports provide the physician with actionable suggestions, each supported by a transparent causative rationale.
Precision Medicine Workflow
Based on the genomic profile of the patient, Cellworks provides patient-specific TRI reports for improved efficacy. Each report includes full transparent patient-specific causal rationale for each therapy suggested. The turnaround time for a Cellworks report is typically 72 hours once an NGS report is produced.